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ABSTRACT 
The incidence in breast cancer has more than tripled in Sweden since the 1960-ies. 
During the same time period the 5-year survival rate has increase from around 65% 
to almost 90%. The survival increase is mainly related to medical treatments 
(endocrine treatments, chemotherapy in different combinations), radiotherapy and 
breast cancer screening. Two thirds of costs for breast cancer are not related to 
these therapies, but to costs outside of the health care system (e.g. early retirement 
and premature death). Continued improvements in therapies would therefore be of 
great gain for the outcome and overall cost of breast cancer. One of these 
improvements has been the discovery of the Human Epidermal Growth Factor 
Receptor 2 (HER2) in the nineteen eighties and the development of the monoclonal 
antibody directed against HER2 (trastuzumab) in the nineteen nineties. 
Trastuzumab is registered for treatment of HER2 positive early and metastatic 
breast cancer. HER2 diagnosis and trastuzumab treatment are dependent on each 
other, as diagnosis is meaningless without the treatment and treatment is 
meaningless without diagnosis. This relationship is usually called co-dependent 
technologies. 
 
The aim of this thesis was to determine how a targeted patient population is 
optimally managed in terms of co-dependent technologies.  
 
The results demonstrate that HER2 testing is not optimally carried out in all 
situations. In 151 patients we found a 10% change in HER2 status between primary 
tumours and relapses (19% from HER2+ to HER2– and 6% from HER2– to HER2+). 
Patients with a change in HER2 status had a significant 5.47 (95% CI 2.01–14.91) 
increased risk of dying compared to patient with stable positive HER2 status (86% of 
these patients received trastuzumab treatment). In another study, there was a 32% 
change in 459 patients in Oestrogen Receptor (ER) status (ER+ to ER- 24.6% ER– 
to ER+ 7.8%). Also ER change is related to worse prognosis and patients with ER 
negative systemic relapses had a significant twofold (95% CI 1.39-2.87) increased 
risk of dying compared to patients with ER positive relapses. This shows that it is 
clinically relevant to re-test relapses for tumour marker status, and changes may 
offer additional treatment options. To be able to follow-up and monitor usage and 
outcome in clinical practice (clinical effectiveness as opposed to use in clinical trials: 
clinical efficacy) treatment with trastuzumab should be used according to guidelines, 
although we found large differences in usage between Health Care Regions (HCRs) 
in Sweden (years 2000-2004 300% difference between North HCR and South HCR, 
years 2006-2008 40% difference between Stockholm-Gotland and South-East and 
West HCRs). Another important aspect is that re-testing of HER2 status before 
trastuzumab treatment in the metastatic setting is cost-effective (USD 56,000 -USD 
67,000 per Quality Adjusted Life Year and USD 39,000 – USD 46,000) and should 
therefore always be done. 
 
Diagnosis of HER2 status and treatment with trastuzumab is a challenge and this 
thesis points to the complexity of co-dependent technologies. The knowledge 
created could be used for the introduction of future co-dependent technologies in 
order to gain the most benefit, both to patients and to society. 
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1 INTRODUCTION 
1.1 Breast cancer epidemiology 
Breast cancer is the most common malignancy among women, with an estimated 
1.4 million women diagnosed with the disease globally in the year 2008. The 
incidence of breast cancer has increased over the years; incidence in Europe was 
around 320,000 women in 1984 and around 424,000 in 2008. This increase is 
estimated to continue with a projected incidence in Europe of 465,000 women in 
2020 (Ferlay et al., 2010). For Sweden the incidence numbers were approximately 
2,500, 5,000 and 7,000 women in 1960, 1990 and 2008, respectively 
(Socialstyrelsen, 2010).  
 
Figure 1 Global incidence and mortality in breast cancer (ASR) 
 
2 
In the USA the incidence in 2008 was 182,000 and the Age Standardise Rates 
(ASR) (WHO, 2001) was 76; Swedish ASR was 79 in 2008, see figure 1 (Ferlay et 
al., 2010). The ASR for 2002 and 2008 were 37.4 and 39.0 in the World and 82.5 
and 84 in Northern Europe, respectively (Ferlay et al., 2010, Parkin et al., 2005).  
 
 
Figure 2 Incidence and mortality in the Nordic countries 1950-2007  
(world ASR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From (Wilking N and Kasteng, 2009) 
 
 
The increased incidence in Sweden (and most other “Western countries”) is mainly 
due to the combined effects of “Western life style factors” as increasing  age, 
overweight, screening, hormone replacement therapy and changed reproductive 
patterns (Kumle, 2008, McPherson et al., 2000, Veronesi et al., 2005). Development 
of adjuvant treatment modalities of breast cancer, starting in the 1970-ties, has 
resulted in a marked decline in relative mortality (Berry et al., 2005, Koscielny et al., 
2009, Nystrom et al., 2002, Clarke et al., 2005, EBCTCG, 2005a). Recent data 
shows in fact that multidisciplinary management teams and adjuvant treatments 
account for the major part of the reduced mortality, while screening only accounts 
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for 1/3 of the reduced mortality (Kalager et al., 2010). Recent studies also discuss 
the reduced mortality in lower age groups being mainly related to access to 
treatment (Autier et al., 2011, Foukakis et al., 2011, Coleman et al., 2011).  
 
Breast cancer survival is high in Sweden and mortality numbers are stable at 
approximately 1,500 women per year since 1990 (Socialstyrelsen, 2009, Sant et al., 
2009, Talback et al., 2003). The relative increase in survival results in an increased 
prevalence of survivors. In 2002 the estimate was that more than 80,000 women in 
Sweden had had a previous diagnosis of breast cancer (Lidgren et al., 2007b). 
 
Although almost 90% of all women in Sweden and around 80% in Europe with a 
breast cancer diagnosis will survive 5 years or more (Ferlay et al., 2010, Coleman et 
al., 2011), some women will have recurrence of the disease (Mirza et al., 2002). At 
the time of relapse it is important to distinguish between an isolated loco-regional 
recurrence versus metastatic disease (Schmoor et al., 2000, Koscielny et al., 2009, 
Malmstrom et al., 2003). Very few patients with metastatic breast cancer will be 
cured and the median survival time is around two years, although patients <60 years 
had a statistically significant increased survival in a population based study in 
Sweden (Foukakis et al., 2011). Around 50% of patients with local relapse and 
around 20% of patients with regional relapse will obtain long-term survival/cure 
(Rausei et al., 2010, Wapnir IL et al., 2006). As in the adjuvant situation, improved 
treatment methods (new drugs, improvements in supportive care) have resulted in 
increased life expectancy for patients with metastatic breast cancer (Kochhar et al., 
2005, Feyer et al., 2008). An increased knowledge of tumour biology has also 
increased the understanding of which patient to treat, at what dose and when to 
treat. This is particularly important for the use of drugs in targeted patient 
populations (Bergh, 2009).  
1.2 Biology of breast cancer. 
Breast cancer is not one disease, but many diseases based on different prognostic 
and predictive factors. Prognostic factors are used for outcome measures in 
untreated patients. Predictive factors are used to define the likeliness of responding 
to a certain treatment.  
4 
The TNM staging system for Tumour size, Lymph node involvement and Metastasis 
is the most important prognostic tool and tumour size and lymph node involvement 
have mostly been regarded as the most important prognostic factors (Singletary and 
Greene, 2003). Below follow brief descriptions of the standard prognostic and 
predictive factors. 
 
Age: Younger women with a breast cancer diagnosis have a worse outcome, even if 
prognosis has improved over time due to adjuvant treatments (Chung et al., 1996, 
Foukakis et al., 2011, EBCTCG, 2005a, Kheirelseid et al., 2011). 
Tumour size: A primary tumour over 2 cm indicates a worse prognosis, with 20 
year disease free survival, DFS, of 64% compared to 79% with tumours with a size 
less than 2cm (Quiet et al., 1995). 
Lymph node involvement: In untreated patients with lymph nodes without tumour 
involvement, the 5 year survival rate is 85% and if there are more or equal to 4 
lymph nodes with tumour involvement the 5 year survival rate is only 26% (Fisher et 
al., 1983). 
Histology: The most common histological grading system is a joint score of  tubule 
formation, mitotic count and nuclear pleomorphism and these are brought together 
and defined as well differentiated (Elston-Ellis I), moderately differentiated (Elston-
Ellis II), poorly differentiated (Elston-Ellis III) (Elston and Ellis, 2002).  
Oestrogen receptor (ER) status and progesterone receptor (PR) status: ER 
positive breast cancer is the most common breast cancer sub-type, and around 50-
80% (related to age) of all women belong to this sub-type (Clark et al., 1984). 
Oestrogen binding to ERs can promote cell growth in breast cancer (Osborne, 
1998). A positive ER status is also a predictor of response to endocrine therapy 
(Jordan, 1988, Ryden et al., 2005, EBCTCG, 2011). A positive PR status is a 
prognostic factor, as it does not alter response to endocrine therapy (Dowsett et al., 
2005, EBCTCG, 2011). 
P53 is a tumour suppressor gene. Patients with breast cancer tumours with loss of 
p53 function (mostly by different types of mutations) have a worse prognosis 
(Hanahan and Weinberg, 2011, Petitjean et al., 2007). 
Human Epidermal Growth Factor Receptor 2 (HER2): Details on HER2 are 
described under section 1.4, as this is one of the main focuses of this thesis. In 
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multivariate analyses, p53 and HER2 have demonstrated to be independent 
prognostic markers (Al-azawi et al., 2011).  
Vascular Endothelial Growth Factor (VEGF) indicate increased angiogenesis and 
is a marker of a worse prognosis in breast cancer (Linderholm et al., 2000). 
 
Advances in molecular medicine, have contributed to an increased understanding of 
the biology of cancer, and have also provided more accurate classification of various 
tumour forms(Elston and Ellis, 2002, Hanahan and Weinberg, 2011, Ottesen et al., 
2000, Urruticoechea et al., 2005, Wirapati et al., 2008, Sorlie et al., 2001, Miller et 
al., 2005, Wennmalm et al., 2009, Pusztai, 2008, Farmer et al., 2009).  
Variations in gene expression patterns derived from cDNA microarrays, separate 
breast cancer into 4-6 sub-groups, luminal (sub-type A-B-C), erbb2+, basal-like, 
normal breast-like. The outcome of for example basal-like is worse and this group 
also has a higher degree of p53 mutations (Sorlie et al., 2001, Sotiriou and Pusztai, 
2009). 
 
 
Figure 3 Cell signal transduction pathways 
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In addition to the molecular separation of breast cancers into several sub-groups, 
there are signalling pathways linked to gene expression, critical for cancer 
development and growth (Alvarez et al., 2010, Hanahan and Weinberg, 2011). 
These pathways affect the transcription of various genes via transmembrane 
proteins and intracellular enzymatic activities. One critical point in these pathways is 
the binding of a ligand (a substance with specific binding capacity), to a 
corresponding extracellular receptor (see figure 3). This ligand binding activates 
various enzyme systems, ultimately resulting in changes in cellular behaviour or 
growth. There are also feed-back mechanisms that have different effects on 
signalling (e.g. Ras, PI3K, Myc) and there are also factors that may circumvent  cell 
growth regulation (e.g. P53, RB) (Hanahan and Weinberg, 2011) (see figure 3). The 
signalling pathways are presently being explored as therapeutic targets; targeted at 
the receptor level or further downstream.  (Ross et al., 2003, Tsourdi et al., 2011, 
Arriola et al., 2011). 
1.3 Pharmacogenomics 
Pharmacogenomics is the influence of normal genetic variation or single nucleotide 
polymorphism (SNP) on drug response in patients by correlating gene expression 
with efficacy or toxicity of a drug (Sachidanandam et al., 2001, Diamandis et al., 
2010). 
A SNP is a normal DNA sequence variation occurring when a single nucleotide in 
the genome (or other shared sequence) differs between individuals or between 
paired chromosomes in an individual (Sachidanandam et al., 2001). Variations in the 
DNA sequences can affect diseases response to pathogens, chemicals, drugs, 
vaccines, and other agents (Cooper DN, 2005, Farmer et al., 2009, Diamandis et al., 
2010). Pharmacogenomics are also thought to be key enablers in the concept of 
personalized medicine (Wang et al., 2011, Diamandis et al., 2010) 
 
Pharmacogenomics aims at developing rational means to “optimize” treatment, with 
respect to genotype of each individual. It explores biological markers that may 
define the right dose, treatment time and avoid adverse reactions in each patient 
(Wang et al., 2011, Albain et al., 2010, Farmer et al., 2009, Diamandis et al., 2010). 
The biological markers in responders in the early clinical trials could then be used in 
larger pivotal studies (Pusztai, 2007). The most commonly known genes that are 
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responsible for variances in drug metabolism and response, is the cytochrome P450 
(CYP) genes (Gomes et al., 2009, Hart et al., 2008). Codeine, tamoxifen, and 
warfarin are examples that follow the CYP metabolic pathways. Cancer related 
genes targeted for treatment are for example EGFR (treatments: cetuximab, 
erlotinib, gefitinib,panitumumab), K-Ras (treatments: cetuximab, panitumumab) and 
HER2 (treatments: trastuzumab, lapatinib) (Wang et al., 2011). 
 
 
Figure 4 HER2 signalling pathway and blocking of dimerization by 
trastuzumab 
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1.4 Human Epidermal Growth Factor Receptor 2 in Breast Cancer 
The Human Epidermal Growth Factor Receptor 2 (HER2) is a cell membrane 
surface-bound receptor tyrosine kinase (Coussens et al., 1985, Hanahan and 
Weinberg, 2011, Slamon et al., 1987). HER2 is one of four members of the HER 
family. The HER2 gene is located on chromosome 17q21-q22 (Coussens et al., 
1985). HER2 is normally involved in the signal transduction pathways controlling cell 
growth and differentiation (Stern et al., 1986). A normal epithelial cell contains two 
8 
copies of the HER2 gene and is defined positive when the gene is amplified. The 
normal number of HER2 on the cell surface is below 20,000 and is defined HER2 
positive at levels over 2,300,000 (Ross et al., 2003). 
HER2 has an independent prognostic value (Slamon et al., 1987, Winstanley et al., 
1991, Seshadri et al., 1993, Al-azawi et al., 2011) and is associated with a general 
poor prognosis, with statistically significant shorter survival time (Ross et al., 2003, 
Sjogren et al., 1998, Revillion et al., 1998). HER2 positive breast cancer indicates 
higher sensitivity to chemotherapy and lower sensitivity to hormonal treatments 
(Dowsett, 2001, Nunes and Harris, 2002). The aspect of heterogeneity of HER2 in 
breast cancer tissue is not clear, but there seem to be different sub-groups of HER2, 
with different characteristics (Wu et al., 2008, Vance et al., 2009, Andersson et al., 
2004, Staaf et al., 2010). HER2 positive early breast cancer has also been 
investigated using gene expression analysis. There are three sub-types of HER2 
positive breast cancer and one of the sub-types has been described to have worse 
outcome (Staaf et al., 2010). There is data on extra cellular HER2 as an indicator of 
prognosis, but this technique is not yet recognised, possibly due to the small series 
in the reports  (Meng et al., 2004, Fehm et al., 2004, Hayashi et al., 2011, Nunes 
and Harris, 2002).  
HER2 positivity is also linked to response to HER2 targeted drugs; the monoclonal 
antibody trastuzumab, directed against the extracellular domain of HER2, (Baselga 
J, 1996), the HER1-HER2 tyrosine kinase inhibitors lapatinib and neratinib (Wood et 
al., 2004, Bose and Ozer, 2009), the HER dimerization inhibitor pertuzumab (Adams 
et al., 2006) and trasuzumab / cytotoxic drug conjugates, TDM1 (Lewis Phillips et 
al., 2008). This thesis is focused on trastuzumab. 
1.4.1 Development of HER2 analysis methods in breast cancer 
The HER2 status is determined by testing of tumour tissue or blood (extracellular 
HER2). In the earliest studies, the HER2 status was determined using Southern blot 
(sequencing method, to reveal the number of DNA copies) (Ross et al., 2003, 
Slamon et al., 1987). Testing strategies for HER2 were later developed in order to 
assess the amount of HER2 protein and number of gene copies (Pauletti et al., 
2000, Pauletti et al., 1996, Liu et al., 1992, Muss et al., 1994, Tsuda et al., 2001, 
Larsimont et al., 2002, Bergqvist et al., 2007). The methods were standardized and 
analyses are nowadays done with Immunohistochemistry (IHC) assays (see table 1) 
at most cancer centres (protein screening method).  
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Table 1 IHC HER2 cut-off levels  
Level 1) Description of cell surface staining 1) No of HER2 2) 
0 
HER2 negative 
No staining, or less than 10% staining of tumour cells  
<20,000  
1 
HER2 negative 
Weak, or hardly visible membrane staining in >10% of 
tumour cells. Membrane staining not complete. 
 
~100,000  
2 
HER2 equivocal 
Weak to moderate complete membrane staining >10% of 
tumour cells 
 
~500,000  
3 
HER2 positive 
Strong complete membrane staining in >30% of tumour 
cells  
 
>2,300,000  
1) (DAKO, 2011)  2) (Ross et al., 2003) 
 
 
The results in the Swedish laboratory quality control program showed that IHC 
results have “good correlation” between laboratories, with kappa-values of 0.67 and 
0.77 in year 2005 and year 2006, respectively (Ryden et al., 2009). 
 
Confirmation of IHC results 
Tumours with HER2 borderline result (IHC 2+) are confirmed with a test of gene 
amplification using an in-situ hybridization method (ISH); fluorescence in-situ 
hybridization FISH is the most recommended method (Wolff et al., 2007, Jacobs et 
al., 1999b, Jacobs et al., 1999a, Couturier et al., 2000, Birner et al., 2001). FISH has 
higher sensitivity (the proportion of correct HER2 positives), as well as higher 
specificity (the proportion of correct HER2 negatives). IHC has 92.6% sensitivity for 
IHC 2+ and 3+ compared to FISH, and 98.8% specificity for IHC 3+ compared to 
FISH and the overall concordance rate was 96.1% for IHC 3+ compared to FISH in 
the Yazij study (Yaziji et al., 2004). If the equivocal results with IHC (2+) are 
included, the specificity is reduced to almost 50% compared to FISH (Tsuda et al., 
2001, Jacobs et al., 1999b, Yaziji et al., 2004). In an overview by Elkin shows that 
around 7% of IHC 0/1+ are FISH positive (Elkin et al., 2004).  
There are some negative factors with the FISH method that in many centres has 
resulted in a decision to use FISH only for confirmation. The FISH method is more 
expensive and time consuming compared to IHC (Yaziji et al., 2004, Jacobs et al., 
1999a) and requires a dedicated pathologist, and thus it is recommended that all 
confirmatory FISH testing is done by few laboratories and well trained staff (Perez et 
10 
al., 2002, Wolff et al., 2007, Mackay et al., 2011). The Swedish inter laboratory 
quality control results for FISH had a “very good correlation” with kappa-values of 
0.92 and 0.96 in year 2005 and year 2006, respectively (Ryden et al., 2009). 
 
Some centres are using another ISH method, Chromogenic In Situ Hybridisation 
(CISH) for screening instead of IHC (a separate confirmation FISH is not usually 
required), or as confirmation for equivocal IHC instead of FISH (Tanner et al., 2000). 
If CISH is used instead of IHC for screening, this will mean that the total time 
required for testing will be shorter and the result is more reliable compared to IHC 
(Gong et al., 2009b). The advantages with the CISH method are that the DNA probe 
is detected using a simple IHC-like peroxidase reaction and the CISH requires no 
specific fluorescence microscope. The results with CISH are also concordant with 
FISH (concordance 97-100%) (Gong et al., 2009a, Gong et al., 2009b, Arena et al., 
2010). As with FISH, CISH detects gene amplified IHC equivocal, 2+ results (Meijer 
et al., 2011).  
1.4.2 HER2 diagnostics in early breast cancer and metastatic breast cancer  
The early studies assumed that HER2 status was stable during disease progression, 
and HER2 status was therefore only analysed in primary tumour tissue (Slamon et 
al., 1987, Cobleigh et al., 1999, Baselga J, 1996). The first data by Slamon in 1987 
showed a 30% proportion of HER positive breast cancer patients. NB! In one cohort 
of patients 18% of tumours were HER2 positive and in another cohort 40% of 
tumours were HER2 positive (Slamon et al., 1987). Studies from Sweden show 14-
19% HER2 positive early breast cancers in a screening environment (Ryden et al., 
2009, Sjogren et al., 1998, Borg et al., 1989). The proportion of patients with HER2 
positive metastatic breast cancer is around 30% (Wilking et al., 2011). The 
differences in the proportion of HER2 positive early breast cancers and metastatic 
breast cancers reflects the fact that HER2 positive breast cancers are more 
aggressive and these patients have an increased risk of developing distant 
metastases. However, studies indicate that tumour cells are not stable, and changes 
in tumour behaviour are seen during tumour development. Between 0-38% of 
patients will have altered HER2 status in recurrences (see table 2). 
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Table 2 HER2 in early breast cancer and recurrence in the same patient 
Publication/ Patients
Abstract Author Number Number Percent Number Percent Number Percent Methods for receptor determination
Neihans 1993 30 1 3 30 100 Immunoperoxidase Technique
Masood 2000 56 1 2 56 100 IHC
Edgerton 2003 113 19 17 20 93 IHC/ FISH
Shimizu 2000 21 0 0 21 100 IHC/ Sandwich Enzyme Immunoassay 
Tanner 2001 46 0 0 33 12 IHC/ CISH
Gancberg 2002 107 10 9 107 100 IHC/ FISH
Sekido 2003 44 2 5 IHC/ FISH
Luftner 2004 80 10 13 IHC
Meng 2004  24 9 38 Immunofluorescence Staining
Zidan 2005 58 8 14 IHC/ FISH
Lipton 2005 240 61 25
£
HER-2/neu Immunosorbent Assay
Gong 2005 60 2 3 43 17 FISH
Solomayer 2006 45 17 38 45 100 IHC/ FISH/ Double Immunofluorescence 
Pectasides 2006 16 6 38 16 100 IHC/ CISH
Wilking 2008 155 18 12 IHC/ FISH
Tapia 2007 105 8 8 105 100 FISH
MacFarlane 2008 160 9 6 IHC
Lidtke 2009 528 72 14 IHC/ FISH
Leitzel 2009 27 5 19 27 Proximity-Based Quantifying Protein 
Lower 2009 382 127 33 382 IHC
Chan 2009 116 18 16 45 71 IHC/ FISH
Broom 2009 100 0 0 100 100 §
* The number of samples within each category not clear from corresponding article 
§
 Methods for receptor determination not clear from article
Table 2: HER-2/neu in primary breast cancers with intraindividual comparisons with the corresponding recurrences
£
 HER-2/neu Oncoprotein Enzyme-Linked Immunosorbent Assay
*
*
*
*
*
*
*
*
Site of relapse
Discordant Patients Local relapse Systemic relapse
 
From (Lindström et al., 2010) 
 
These results are being challenged and there are discussions whether the changes 
are artefacts or reflect biology and therefore are of real clinical importance (Khasraw 
et al., 2011, Pusztai et al., 2010). 
 
1.5 Breast Cancer treatment 
The breast cancer diseases are treated with different technologies for short or long 
periods of time. The most important treatments are surgery, radiotherapy (EBCTCG, 
2005b), chemotherapies and endocrine therapies (Benson et al., 2009).  
 
The types of treatments offered, are based on the prognostic and predictive factors 
described earlier. As also described earlier, medical treatments have contributed the 
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most to the increased survival of breast cancer. The two major medical treatment 
types, for patients with increased risk of recurrence, are chemotherapy combinations 
and endocrine therapies. Adjuvant treatments are also guided by a risk-benefit 
analysis, where risks of recurrence are weighted against the adverse effects of 
treatment (Goldhirsch et al., 2011, EBCTCG, 2005a, EBCTCG, 2011).  
Chemotherapy inhibits cell growth by different mechanisms of action. 
Chemotherapy in various combinations has been developed over more than 40 
years and combinations containing an anthracycline or a taxane are regarded to be 
most effective. Adjuvant chemotherapy provides a long term survival increase of 
absolute 15% and 10% in patients with lymph node positive disease and lymph 
node negative disease, respectively (EBCTCG, 2005a). The later updates show that 
the survival advantage remained (EBCTCG, 2007). 
Endocrine therapy blocks the effect of hormones on cell proliferation. In post 
menopausal women, with hormone dependent disease, tamoxifen is most widely 
used, partly replaced by the Aromatase Inhibitors (AI) (anastrozol, exemestane, 
letrozol) (Burstein et al., 2010). In pre menopausal women, with hormone dependent 
disease, increased survival can be achieved by tamoxifen alone, or combined with 
ovarian ablation (surgery, radiotherapy or a gonadotropin-releasing 
hormone,GNRH-agonist) (EBCTCG, 2005a). Tamoxifen provide over 30% reduced 
15-year mortality (EBCTCG, 2011) and AIs reduces the risk of relapse with around 
4% compared to tamoxifen, but no gain is seen in Overall Survival (OS) (Burstein et 
al., 2010, Dowsett et al., 2010). 
 
1.5.1 Treatment for HER2 positive breast cancer  
1.5.1.1 Trastuzumab 
The monoclonal antibody, trastuzumab (Herceptin ®, F. Hoffman-La Roche Ltd 
Basel Switzerland), targets the extracellular domain of the HER2 protein and blocks 
the corresponding down-stream signalling pathway (see figure 4). Trastuzumab was 
registered in the EU in year 2000 for the treatment of HER2 positive metastatic 
breast cancer, having already been approved in USA in 1998. The adjuvant 
indication was approved in 2006 by EMA for EU (shortest process ever, around two 
months), followed by the FDA approval for USA. 
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Trastuzumab has relatively few side effects, with cardiac side effects as the major 
concern. The frequency of Congestive Heart Failure (CHF) is in the order of 2-4.3% 
of patients and LVEF drop (symptomatic and asymptomatic) is found in around 4-
27% of patients (this varies largely between reports, related to the set levels of 
LVEF drop) (Dang et al., 2010, Perez et al., 2008, Suter et al., 2007, Slamon et al., 
2001). The cardiac toxicity is often reversible and around 50% of patients can restart 
with trastuzumab treatment again after LVEF recovery (Dang et al., 2010, Perez et 
al., 2008). This is in contrast to the anthracycline related cardiac toxicity, which is 
not reversible and carries a long time risk of cardiac failure (Mulrooney et al., 2009). 
1.5.1.2 Trastuzumab in Metastatic Breast Cancer 
The Phase II data showed tumour responses with single agent trastuzumab in11-
15% of patients (Baselga J, 1996, Cobleigh et al., 1999, Vogel et al., 2001). The 
combination of trastuzumab and taxane based chemotherapies have been studied 
in metastatic breast cancer. In those studies the addition of trastuzumab provided 
statistically significant survival improvements in HER2 positive patients by 5-8.5 
months. In this patient population the median survival time was 20-22.5 months 
without trastuzumab treatment (Marty et al., 2005, Slamon et al., 2001). In the study 
by Slamon the cardiac dysfunctions were seen in 27% of patients randomised to the 
combination of an anthracycline and trastuzumab (Slamon et al., 2001). 
Trastuzumab may also be combined with vinorelbine for metastatic breast cancer 
with similar survival and fewer side effects compared with the standard docetaxel 
combination (Andersson et al., 2011).  
NB! In an interesting comparison between targeting patients with HER2 positive 
disease versus treating an unselected patient population, Simon calculated that 
23,586 patients would have been required to detect similar survival differences in 
the studies instead of the 469 patients included (Simon and Maitournam, 2004). 
 
In a study in postmenopausal metastatic breast cancer patients, with HER2 and ER 
positive primary cancer (the TAnDEM studie), trastuzumab in combination with the 
AI anastrozole increased progression free survival (PFS) from 2.4 months (95% CI 
2.0- 4.6 months) without trastuzumab to 4.8 months (95% CI 3.7-7.0 months) with 
trastuzumab (P= 0.0007), although the OS difference was not significant (70% of 
14 
patients in the anastrozole alone arm crossed over to treatment with trastuzumab) 
(Kaufman et al., 2009).  
1.5.1.3 Trastuzumab in Early Breast Cancer 
Adjuvant trastuzumab treatment for 12 months in combination/sequence with 
different types of chemotherapy results in an absolute disease free survival 
improvement of 6-12%, and a relative recurrence risk reduction of around 50% in 
women with HER2 positive early breast cancer (Gianni et al., 2011, Romond et al., 
2005, Slamon, 2009, Smith et al., 2007, Piccart-Gebhart et al., 2005, Perez et al., 
2011). In the latest update at 4 years, the OS benefit of trastuzumab remained (HR 
0.61 95% CI 0.50-0.75) (Perez et al., 2011), although this benefit was not seen in 
another adjuvant study, with a 4-year HR 0.85 (95% CI 0.70-1.04; p=0.11) (Gianni et 
al., 2011). There is also data on a shorter treatment time of 9 weeks, but the initial 
effect on survival (3 year PFS 89% vs. 78% without trastuzumab) was reduced with 
time (5 year HR for recurrence 0.65, 95% CI 0.38-1.12 p=0.12). Thus, the 
recommended adjuvant treatment time remains at 12 months. 
1.5.1.4 Trastuzumab in comparison to lapatinib in Breast Cancer 
The HER1 and HER2 tyrosine kinase inhibitor lapatinib has obtained conditional 
approval in the EU for treatment of metastatic breast cancer patients, failing first line 
treatment with chemotherapy and trastuzumab. However, an update of the feasibility 
study revealed a reduced PFS time compared with the initial report (Cameron et al., 
2008, Geyer et al., 2006). In addition, the German randomized GBG 26 study 
showed that maintaining trastuzumab, but shifting chemotherapy to capecitabine, 
after progression could result in similar effects (median PFS 5.6 months in the 
capecitabine group and 8.2 months in the capecitabine+trastuzumab group), 
although with no statistical significant OS survival gain (capecitabine: 20.4 months, 
95% CI 17.8-24.7, capecitabine+trastuzumab: 25.5 months, 95% CI 19.0-30.7, P = 
0.257) in this study including only 156 patients (von Minckwitz et al., 2009). 
Blackwell and colleagues demonstrated that the combination of trastuzumab and 
lapatinib provided better PFS (HR 0.73, 95% CI 0.57-0.93) compared to lapatinib 
alone, in patients progressing on trastuzumab, although there was no statistically 
significant difference in OS (HR 0.75, 95% CI 0.53-1.07) (Blackwell et al., 2010). 
The neoadjuvant GBG 44 study also demonstrated that trastuzumab provides higher 
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response rates (31.3% pathologic Complete Response, pCR) compared to lapatinib 
(21.7% pCR, P=0.05) (Untch M et al., 2010). In The Adjuvant Lapatinib And/Or 
Trastuzumab Treatment Optimisation study (ALTTO), it was just decided to offer 
trastuzumab to all patients who initially were randomised to lapatinib, indicating 
increased recurrence rates or toxicity to lapatinib (personal communication 
September 2011). 
1.5.1.5 Novel treatment in HER2 positive Breast Cancer 
Pertuzumab is a monoclonal antibody, the first of its class in a line of agents called 
"HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of 
HER-mediated signaling pathways, which is hypothesized to result in slowed tumour 
growth (Adams et al., 2006). The response rate in trastuzumab failing metastatic 
breast cancer patients is around 24% (Complete Responses, CR, 7.6%, 80% CI 3.7-
13.6%, Partial Response, PR, 16.7%, 80% CI 10.9-24.1) (Baselga et al., 2010). 
Neo-adjuvant results show that the combination of pertuzumab, trastuzumab and 
docetaxel obtained higher proportion of pCR (88% p= 0.014) compared to the 
combination without pertuzumab (80% pCR) (Gianni L et al., 2010).  
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1.6 Health Economic aspects 
In Sweden (population 9.4 million) direct costs (health care related) of breast cancer 
were in 2002 estimated to be SEK 900 million (USD 125 million) and indirect costs 
(all other costs) to be SEK 2.1 billion (USD 292 million) (Lidgren et al., 2007a). As a 
reference, the estimated cost of breast cancer in USA was USD 13.9 billion in 2006 
(NCI:, 2010). This cost translates to a total cost (direct + indirect costs) per incident 
case in Sweden to USD 57,000 and in USA to USD 76,000 (NB! These figures 
should be read with caution and reflect differences in the health care systems’ 
expenditure). 
 
We have seen increasing costs for cancer drugs over the last decade, as there have 
been introductions of several new innovative drugs. Data shows that this has been a 
correct approach, as usage of new cancer drugs result in a statically significant 
reduced mortality and can be of good value for society (Luce et al., 2006, 
Lichtenberg, 2011, Lichtenberg et al., 2009). In general, investments in health care 
are of good value for money, especially investments in breast cancer (Luce et al., 
2006). 
 
Health economic studies are important as a basis for developing guidelines for 
resource allocation in health care systems (Jonsson, 1997, Karlsson and 
Johannesson, 1996), reflecting the limited resources in health care systems 
(Eckerlund et al., 1995). However, assessments and appraisals of new cancer drugs 
have surfaced a new policy issue of clinical consequences, since reimbursement 
decisions may delay access to new therapies. An example is the appraisal of 
trastuzumab in the UK (two years after approval) (NICE, 2002). In general, the use 
of Health Technology Assessments (HTA) is important for an overall perspective of 
the benefit of an intervention. HTA has developed over many decades and should 
include all aspects of the intervention (e.g. demographics, disease panoramas, 
treatment efficacy, effectiveness variation in health practices, cost-effectiveness, 
social and ethical aspects) (Jonsson, 2009). It is also important that health economic 
studies are made relevant for the country or the situation, as health care systems 
differ (Drummond et al., 2005). One important aspect in assessing value for money 
is the perspective on cost. The guiding principle should be to include all relevant 
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costs in the estimates, also costs outside of the health care system (Johannesson M 
et al., 2009, Lidgren et al., 2007a).  
Decisions about clinical strategies must take all factors into account and develop 
knowledge on the effectiveness of an intervention (use in clinical practice, as 
opposed to the use in clinical trials) (Frueh, 2010, Nilsen, 2011). Comparative 
Effectiveness Research (CER) is the direct comparison of existing health care 
interventions to determine which work best for which patients and which pose the 
greatest benefits and harm (Berry, 2011, Steinfort et al., 2011). At the American 
Society for Clinical Oncology this year the plans for a large study on CER in 
adjuvant breast cancer patients was presented (Ramsey, 2011). This is an important 
step in the direction towards true effectiveness evaluations.  
1.6.1 The co-dependent technologies HER2 testing and trastuzumab treatment 
The testing for HER2 and treatment with trastuzumab has important health 
economic implications. The first is about optimal testing strategies. Which test 
should be used, and what cut-off points should be set for confirmatory testing? The 
answer to this question depends on the characteristics of the available tests 
(sensitivity, specificity) (Wolff et al., 2007, Yaziji et al., 2004), as well as to costs. 
The second aspect relates to the optimal treatment strategy, taking into account 
outcome in terms of survival and quality of life, side effects, as well as to costs in 
relation to the defined targeted patient population. Trastuzumab treatment costs and 
outcome are also related to the length of treatment (Joensuu et al., 2009, Joensuu 
et al., 2006, Slamon, 2009). These two aspects are not independent and the optimal 
testing and treatment strategies have to be analysed together. HER2 testing and 
trastuzumab treatment is an example of co-dependent technologies. Testing without 
treatment is meaningless unless a special value is assigned to the information about 
prognosis. Treatment can be undertaken without testing, but cost-effectiveness will 
be lower; perhaps even so low that it is not worthwhile. Price can of course be 
adjusted to reflect cost-effectiveness, but the benefit will always be less favourable 
when patients with no or minor benefit are exposed to treatment. 
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1.6.2 Cost of HER2 testing and treatment with trastuzumab 
In Sweden the HER2 testing cost is around SEK 1,800 (USD 250) and SEK 5,300 
(USD 750) for IHC and FISH, respectively (Sjukvårdsregionen, 2011).  According to 
the Swedish guidelines, every patient with early breast cancer should be HER2 
tested with IHC and confirmed with FISH for IHC borderline and positive results. The 
guideline also state that recurrent sites should be HER2 tested (SweBCG, 2011). 
HER2 testing of recurring breast cancer is uncommon in other countries, even if 
data shows that tumours change in HER2 status (as well as in other tumour 
markers). (Lindström et al., 2010). If testing is carried out on all 7,300 women 
diagnosed per year in Sweden, the cost of testing early breast cancers would be 
over SEK 40 million (USD 5.5 million) and for metastatic breast cancers (FISH for 
all) around SEK 8 million (USD 1 million). Testing cost is also a one off cost and 
therefore far out priced by treatment cost (see below), as this is an ongoing cost. 
 
Breast cancer is a very drug intense disease (around 10% of direct costs, increasing 
due to new innovative drugs). Even so, in Sweden only about 1/3 of the total costs 
of the disease relate to direct costs (e.g. hospitalisation and drugs) and 2/3 relate to 
indirect costs, such as loss of work capacity, sick leave and mortality (Lidgren et al., 
2007a). Total spending on cancer drugs in Sweden is at a similar level (12%), but 
the indirect costs are lower and constitute around 50% of cost (Cancerfonden, 
2006). The cost of the trastuzumab drug is around SEK 25,000 (USD 3,850) per 
month in Sweden and the total sale for trastuzumab for 2010 was around SEK 323 
million (USD 45 million). The cost of trastuzumab treatment is an additional cost to 
the previous standard of care, as the drug was first in class for the treatment of 
HER2 positive breast cancer. There are health economic studies showing that 
HER2 testing and treatment with trastuzumab in breast cancer patients in Sweden is 
cost-effective with an ICER of SEK 485,000 to SEK 560,000 in the metastatic breast 
cancer setting and SEK 333,000 to SEK 385,000 in the adjuvant setting  (Lidgren et 
al., 2008a, Lidgren et al., 2008b). Without the HER2 testing trastuzumab treatment 
would probably never reach a cost-effectiveness level, as the numbers of patients 
required for statistically significant survival benefit would never have been reached 
in the clinical trials (Simon and Maitournam, 2004). 
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1.6.3 Quality Adjusted Life Years  
Quality Adjusted Life Year (QALY) is a measure of disease burden, including both 
the quality and the quantity of life lived (Doctor et al., 2004). In health economics it is 
used in assessing the value for money of a medical intervention (Jonsson, 1990). 
The QALY is based on the number of years of life that would be added by the 
intervention, Life Years Gained (LYG). Each year in perfect health is assigned the 
value of 1.0 down to a value of 0.0 for death. If the extra years would not be lived in 
full health, then the extra life-years are given a value between 0 and 1 to account for 
this.  
The advantages of using QALY as the outcome measure in economic evaluations, 
is that it can combine different consequences into one measure, and that makes 
comparisons possible between interventions affecting Quality of Life (QoL) with 
interventions affecting life expectancy. The acceptance of QALY differs and is not 
always useful, for instance in relation to survival in cancer (Tengs, 2004). 
1.6.4 Cost effectiveness Analysis 
Cost Effectiveness Analysis (CEA) is used to make informed decisions about 
allocation of resources to achieve the greatest improvement in health in a budget 
constrained environment (Jonsson, 1993). CEA compares the costs and outcomes 
of two or more interventions. Normally CE is expressed as a ratio, where the 
denominator is the change in effect, e.g. LYGs or QALYs gained (also called Cost 
Utility Analysis, CUA), and the numerator is the change in cost. The ratio is 
Incremental Cost Effectiveness Ratio (ICER). To make a correct calculation of ICER 
it is important that each intervention is compared to the next most effective, non-
dominated intervention. The concept of dominance refers to the fact that some 
alternatives are inferior to others. There are two types of dominance. Simple 
dominance occurs when an intervention, in absolute terms, is more effective and 
less costly than another. Extended dominance occurs when an intervention with 
higher effect has a lower ICER, i.e. the more effective intervention costs more in 
absolute terms but is less costly per gained effect unit. 
One important methodological consideration when calculating cost-effectiveness 
ratios is what costs to include. While the guiding principle should be to include all 
costs (but only once), practices vary. Health care payers in many countries will not 
include all the societal costs in their studies, although the total value of an 
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intervention should include the societal perspective (Johannesson M et al., 2009). In 
Sweden on the other hand, it is recommended to use the societal perspective for 
reimbursement evaluations (Läkemedelsförmånsverket, 2003). 
1.6.5 Modelling technique / Markov model 
A model is a simplified description of a complex process and the consequences of 
different actions. The Markov model is a transition model, used to study health 
states that recur and change over time. These health state changes are called 
transitions and are described by probabilities. The decision process is not linear, so 
the evolving disease pattern must be accounted for in the transitions. For example, 
a Markov model could be used for analyzing the progression and relapse of a 
chronic disease and treatment outcomes over a specific period of time (Sonnenberg 
and Beck, 1993).  
 
Figure 6 The Markov model 
 
1.6.6 Willingness to pay  
In economics, the willingness to pay (WTP) is the maximum amount a 
person/society would be willing to pay, sacrifice or exchange in order to receive a 
benfit or to avoid something undesired.  
 
It is difficult to set a benchmark level of WTP, even if attempts have been made to 
make estimates (Culyer et al., 2007, Eichler et al., 2004). For example, the National 
Institute for Health and Clinical Excellence (NICE) in the United Kingdom set a level 
in 2008 for health care of BP 20,000- 30,000 per QALY. A study that translated data 
from road accidents to health care, estimated the Swedish WTP for a QALY at SEK 
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655,000 (USD 91,100) (Persson and Hjelmgren, 2003). In USA the levels of USD 
100,000 to USD 300,000 in health care for a QALY saved are discussed 
(Braithwaite et al., 2008). 
 
The more society is willing to pay for improvements in health, the more society is 
willing to pay for interventions that will improve health. An intervention will not be 
adopted if the WTP per QALY gained is not at an acceptable level. If the price per 
QALY gained is set at the optimal level, CEA will maximise the use of social welfare 
(Johannesson M et al., 2009).  
 
2 RATIONALS FOR THIS THESIS  
In the future, many cancers will be (some already are) defined by different genetic 
factors besides the standard diagnostic criteria (so far mostly based on different 
morphology criteria). Diagnoses and treatments of breast cancer are becoming 
more complex, due to the different sub-groups (Goldhirsch et al., 2011). There are 
already some important breakthroughs (e.g. trastuzumab for the HER2 positive sub-
group), based on this new knowledge, established from different gene expression 
defined sub-groups (Sorlie et al., 2001).  
 
The introduction of a drug like trastuzumab, based on a predictive marker is nothing 
new. Tamoxifen and ER status is the first example in breast cancer (EBCTCG, 
2005a, EBCTCG, 2011, Rutqvist, 1990). The new aspect is that co-dependent 
technologies are developed based on knowledge from disease biology and that they 
are introduced jointly to the health care system.  
 
A diagnostic test combined with a targeted treatment raises questions on the test 
procedures and the related treatment options. The test is important, as it may offer a 
prognostic value. It may also offer a predictive value, as it may reduce the number of 
patients required in the pivotal clinical studies and provides information on which 
patients could benefit from treatment (Simon and Maitournam, 2004). The treatment 
is important as it may affect outcome with increased response rates and prolonged 
survival (Marty et al., 2005, Romond et al., 2005, Slamon, 2009, Slamon et al., 
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2001). Thus, it is important to make best use of the knowledge accrued of how these 
patient populations should be managed in terms of co-dependent technologies.  
 
In Sweden we have a personal identification system for each of the nation’s 
inhabitants. It is a unique ten digit identification number, making it possible to track 
individuals through their whole life, in any logistic system. This makes Sweden very 
well suited for follow-up and observational studies. 
 
3 AIMS OF THIS THESIS 
The overall aim of this thesis was to determine how a targeted patient population is 
optimally managed.  
 
The aims of the papers included were: 
Paper 1 (HER2 status in primary tumours and recurrences). 
Investigate the correlation of intra-individual HER2 status between primary breast 
cancers and corresponding recurrences in a population derived cohort. 
Paper 2 (Clinically used breast cancer markers are instable throughout tumour 
progression). 
Assessing intra-individual ER status, PR status and HER2 status in primary tumour 
and first relapse and later relapses, and relate altered and unchanged oestrogen 
receptor status to survival, in a large homogenous cohort of breast cancer patients. 
Paper 3 (Uptake and use of trastuzumab in Sweden during the years 2000-
2008). 
Study the introduction and usage of trastuzumab in breast cancer patients in the six 
Health Care Regions (HCRs) in Sweden.  
Paper 4 (Cost-effectiveness of HER2 re-testing and trastuzumab treatment in 
patients with metastatic breast cancer). 
Study cost-effectiveness of re-testing HER2 status in metastatic breast cancer 
tumour samples from patients before offering trastuzumab treatment in a Swedish 
setting. 
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4 MATERIALS AND METHODS 
This thesis is based on data from registries, databases and retrospective studies of 
available data in databases and patient records. The projects required were 
approved by the Ethics Committee at the Karolinska Institutet. 
 
The following data sources were used for the entire thesis: 
 Data on breast cancer patients retrieved from the Breast Cancer Registry in 
Stockholm, with recurrent diagnosis years 1997-2007.  
 Data from the Swedish Cancer Registry and Statistics Sweden. 
 Sales of trastuzumab for years 2000-2008 from Apoteksbolaget (Pharmacy 
wholesaler) 
 Price list for the Stockholm County from 1 April 2010. 
 Encoded observational patient database with 225 metastatic breast cancer 
patients, diagnosed with metastatic disease years 1997-2007 in Stockholm.  
 HER2 status results, diagnosis and treatment details on patients with relapse 
diagnosis at the Karolinska University Hospital in Stockholm. 
 HER2 status results from the pathology departments in Linköping (South East 
HCR) and Lund (South HCR). (no individual data) 
 Database on HER2 status and other data retrieved from patient records in 
three out of the six health care regions (HCR) in Sweden: Umeå (North 
HCR), Uppsala (Uppsala-Örebro HCR) and Stockholm (Stockholm-Gotland 
HCR), in total data from ca. 600 patients (supportive data). 
 
For the individual projects the following materials and methods were used: 
For paper 1 (HER2 status in primary tumours and recurrences), data on the 
Stockholm metastatic breast cancer patient cohort years 1997-2007 were obtained 
from the Regional Breast Cancer Registry in Stockholm. HER2 status results for 
these patients were retrieved from the Departments of Pathology at the Karolinska 
University Hospital in Stockholm and St Göran hospital. Data on trastuzumab 
treatment for these patients was retrieved from individual patient files.  
IHC/ICC analyses were carried out on primary tumours and recurrence (internal 
control consisted of four breast cancer cell lines: BT474 3+, MDA453 2+, RT4 1+, 
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and 5637 0). FISH was carried out if the IHC/ICC protein level was 2+ or 3+, or 
direct FISH. 
 
Paper 2 (Clinically used breast cancer markers are instable throughout tumour 
progression): Data on the Stockholm metastatic breast cancer patient cohort years 
1997-2007 was obtained from the Regional Breast Cancer Registry in Stockholm 
(bilateral and primary metastatic disease excluded). ER and PR status were 
assessed either by monoclonal antibody-based biochemical methods (> 0,05 
fmol/µg DNA positive), by immunohistochemistry (IHC) or by immunocytochemistry 
(ICC) (> 10% positive) (Lofgren et al., 2003). IHC/ICC methods were used for 
determination of HER2, confirmed by FISH for HER2 IHC/ICC equivocal 2+ and 
positive 3+. 
 
Paper 3 (Uptake and usage of trastuzumab in Sweden): Data from the Swedish 
Cancer Registry, the Cause of Death registry by the National Board of Health and 
Welfare (Socialstyrelsen) were used. For general statistics, Statistics Sweden was 
used. Sales data was received from Apoteksbolaget (Pharmacy wholesaler). Data 
from the pathology departments in Umeå, Uppsala, Stockholm Linköping and Lund 
were retrieved from the local databases.  
 
Paper 4 (Cost-effectiveness of HER2 re-testing and trastuzumab treatment in 
patients with metastatic breast cancer): The price list for Stockholm County was 
used for cost estimates. Effects were taken from the Marty study (Marty et al., 
2005). Quality of Life (QoL) data was taken from the Lidgren study in 2007 on QoL 
in different states of breast cancer (Lidgren et al., 2007b). HER2 testing results and 
test specifics were taken from the estimates by Elkin in 2004 (Elkin et al., 2004). Six 
different testing/treatment strategies were used (see table 3), with the reference 
base case of no re-testing and no trastuzumab treatment. 
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Table 3 Re-testing and treatment strategies for HER-2 positive  
Metastatic Breast Cancer 
 
Strategy 
Testing of metastasis Treatment 
IHC FISH Trastuzumab + Chemo Chemo 
0 - - - All 
1 - - If primary tumour was HER2+ Others 
2 Yes - If IHC 3+ Others 
3 Yes - If IHC 2+ or 3+ Others 
4 Yes If IHC 2+ or 3+ If FISH+ Others 
5 - Yes If FISH+ Others 
 
 
 
4.1 Statistical methods 
Paper 1 (HER2 status in primary tumours and recurrences): The Agreement 
between assessments was calculated by kappa statistics, according to Landis and 
Koch (Landis and Koch, 1977). For the survival analyses, follow-up started at the 
date of breast cancer diagnosis and continued either until date of death or until 
censoring (end of follow-up of December 31, 2007). A univariate analysis (Kaplan-
Meier method) was used for overall survival. The risk of dying was modelled by use 
of a multivariable proportional hazard (Cox) model, adjusted for age, year of 
diagnosis, oestrogen and progesterone receptor status (Schoenfeld, 1982). The 
proportional hazard assumption was assessed using Schoenfeld’s test 
statistics(Schoenfeld, 1982). An arbitrary level of 5% statistical significance was 
used and 95% confidence intervals (CI) were calculated.  
 
Paper 2 (Clinically used breast cancer markers are instable throughout tumour 
progression): Univariate analyses of overall survival from either primary tumour 
diagnosis or relapse were performed in patients according to intra-individual ER 
status in primary tumour and relapse, using the Kaplan-Meier method.  
The risk of dying in relation to ER status in primary tumour and relapse was 
modelled using a multivariable proportional hazard (Cox) model, adjusting for 
potential confounding factors (age and calendar year of primary breast cancer 
diagnosis, PR status, tumour stage, adjuvant hormonal therapy and adjuvant 
chemotherapy). The proportional hazard assumption for the main exposure variable 
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was assessed using Schoenfeld’s test statistics. An arbitrary level of 5% statistical 
significance (two-tailed) was used.  
 
Paper 3 (Uptake and usage of trastuzumab in Sweden): The analyses were 
based on the following assumptions: 25% HER2 positive metastatic breast cancer 
patients (Slamon et al., 1987, Wilking et al., 2011). and 38 weeks treatment time 
(Slamon et al., 2001) (and our database described earlier), 14% HER2 positive early 
breast cancer patients (Ryden et al., 2009) and 52 weeks treatment time (based on 
drug label). 
Sales data on trastuzumab was used to calculate the actual use. The “optimal” use 
was based on the total number of patients in need of treatment, based on incidence- 
and mortality data for each HCR. 
 
Paper 4 (Cost-effectiveness of HER2 re-testing and trastuzumab treatment in 
patients with metastatic breast cancer): We used a Markov state transition model 
to simulate six different strategies for re-testing and treatment (see table 1 in 
Materials and Methods). The analyses were based on treatment guidelines 
according to the label and published data (Elkin et al., 2004, Marty et al., 2005). 
QALY weights and risks of progression and breast cancer death were taken from a 
previous study (Lidgren et al., 2008b). Outcomes are measured as LYG and QALYs 
gained and costs, including both direct and indirect costs. For the modeling we used 
the program TreeAge Pro 2009 (TreeAge Software, Inc., Williamstown, MA). 
Analyses were performed with life time perspective and both costs and outcomes 
were discounted at 3%. 
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5 RESULTS 
Paper 1 (HER2 status in primary tumours and recurrence): The total sample 
cohort consisted of 1181 breast cancer patients with recurrent disease. Baseline 
patient and tumour characteristics are described in table 4. 
 
 
Table 4 Patient and tumour characteristics 
Patient 
group 
(total in 
category) 
Median 
age  
(range) 
Median 
time to  
recurrence  
in months 
(range) 
Clinical stage % 
1) 
Histop. 
grade 
(Elston)    
2) 
ER/PR 
positive  
%   
3) 
Adj. 
Chemo. 
% 
Adj. 
Hormone 
treatment 
% 
Adj. 
trast
. 
% 
1 2 3 4 2 3  
HER2  
Negative 
stable (101) 
53 
(28-85) 
 
28.7 
(0-152) 
28 45 20 1 8 14 34 57 55 0 
HER2  
Positive 
stable  (35) 
51 
(28-83) 
22 
(0-65) 
17 60 17 0 3 8 14 80 34 11 
HER2 
change (15) 
56 
(30-78) 
22.3 
(7.9-97.9) 
25 50 25 0 1 4 25 63 56 1 
Total sample  
(excluding 
study 
sample) 
(1021) 
56  
(23-97) 
64.3 
 
44 37 14 1 - - 34 37 55 NA 
1) 5 patients in the HER2 neg stable group, 2 patients in the HER2 pos stable group, 0 patients in the HER2 
change group, respectively had no clinical stage defined. 
2) 81 patients in the HER2 neg stable group, 24 patients in the HER2 pos stable group, 9 patients in the 
HER2 change group, respectively had no Elston defined. No patient had an Elston grade 1 cancer. 
3) 28 patients in the HER2 neg stable group, 6 patients in the HER2 pos stable group, 6 patients in the HER2 
change group, respectively had no ER/PR result available. 
 
 
 
In 368 patients HER2 status was analyzed in a recurrence (mostly from Fine Needle 
Aspirates (FNA) samples). In 151 of these patients, HER2 status was also available 
from primary tumour samples. The sites of recurrence are listed in table 5. 
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Table 5 Sites of recurrence  
Site of recurrence Numbers Proportion % 
Bone/bone marrow 45 30 
Liver 24 16 
Local 27 18 
Lung/pleura 15 10 
Axillary lymph nodes 13 9 
Skin (not local) 10 7 
Other sites 9 7 
Supra clavicular lymph nodes 8 5 
Total 151 100 
 
 
IHC analyses were carried out on 144 primary tumours and 86 samples were 
analysed with FISH. In the recurrence samples the corresponding numbers were 84 
for IHC/ICC and 102 for FISH. 
 
In 10% (15 patients) of all patients HER2 status changed from primary tumour to 
recurrence. In 19% (8 patients) of the patients with HER2 positive early breast 
cancer the relapse was HER2 negative and 6% (7 patients) of the patients with 
HER2 negative early breast cancer had HER2 positive relapse. Intra-patient 
agreement in HER2 status was 76% (95% CI 64-87%), and the disagreement was 
10% (95% CI 5-15%).  
 
In the group of patients with unchanged HER2 negative status 24% and of the 
patients with a change in HER2 status 6% had triple negative (ER negative, PR 
negative, HER2 negative) primary breast cancer.  
 
The multivariable Cox analysis showed a significant increased risk of dying in the 
patient group with changed HER2 status compared with patients with concordant 
positive HER2 status (see table 6).  
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Table 6 Risk of death in breast cancer patients related to intra-individual  
HER2 status in primary tumour and relapse. 
 
 
 
Trastuzumab was administered to 77% of the patients with HER positive primary 
tumours (12% adjuvant and 82% for recurrence disease, 6% unknown date). For 
patients with HER2 positive metastatic disease, 76% received trastuzumab 
treatment (94% recurrent disease, 6% unknown date). For patients with stable 
HER2 positive status, 86% received trastuzumab (13% adjuvant 77% recurrence, 
10% unknown date) and only 33% of patients with changed HER2 status received 
trastuzumab.   
 
Paper 2 (Clinically used breast cancer markers are instable throughout tumour 
progression) ER, PR and HER2 status was found in a total of 845, 836 and 356 
patients, respectively, of the 1010 breast cancer patients diagnosed with relapse 
from 1997 through 2007 (bilateral and primary MBC excluded). Of these patients, 
71.9% were ER positive, 58.8% PR positive and 27.9% HER2 positive.  
In 459, 430, and 104 patients, respectively, ER, PR and HER2 status was assessed 
in both primary tumour and first relapse. A change in 32.4% (ER), 40.7% (PR) and 
14.5% (HER2) of patients was seen. In 119 (ER), 116 (PR) and 32 (HER2) patients, 
respectively information from multiple relapses was available. When comparing 
several relapses, 33.6% (ER), 30.1% (PR) and 15.7% (HER2) of patients showed 
altered marker status. Furthermore, 16.0% of patients had changed ER status from 
Intra-individual 
HER2 status in 
primary tumour 
and relapse  Patients Deaths  
                           
Overall survival 
from breast 
cancer diagnosis 
to death or 
censoring 
                                  
Overall survival from 
relapse to death or 
censoring 
Her-2 status No % Overall 
Adjusted*                
HR (95% CI) 
Adjusted*                 
HR (95% CI) 
Positive 34 23.1 18 1.0 ref. 1.0 ref. 
Discordant 14 9.5 10 5.47 (2.01-14.91) 3.22 (1.18-8.77) 
Negative 99 67.3 71 1.85 (0.99-3.45) 2.38 (1.27-4.43) 
*Adjusted for age and year of diagnosis, oestrogen receptor status, progesterone receptor status and stage 
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positive to negative and 12.6% had changed from negative to positive. Actually, 5% 
of patients had altered ER status back and forth between relapses. 
 
 
Figure 6 Overall breast cancer survival (primary tumour diagnosis to death or 
censoring). Intra-individual ER status in primary tumour and relapse (both 
local and systemic relapses included 
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In the Cox proportional hazard survival model from early breast cancer diagnosis to 
death or censoring at end of follow-up, patients with change in ER status from 
positive to negative, had a statistically significant increased hazard ratio (HR) for 
dying, including both local and systemic relapses (HR 1.61, 95% CI 1.17-2.21) and 
including systemic relapses only (HR 2.00, 95% CI 1.39-2.87), compared to patients 
with stable positive ER status.  
 
 
Paper 3 (Uptake and usage of trastuzumab in Sweden) shows that the use of 
trastuzumab differs greatly between HCRs in Sweden. During the years 2000 to 
2004, when the drug was approved only for treatment of metastatic breast cancer, 
there were very large differences in usage between HCRs. For example the South 
HCR had 30% of the usage of the North HCR (see figure 7). The usage during years 
2006-2008, with both metastatic and adjuvant use, is shown in figure 8. 
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Figure 7 Proportion usage years 200-2004 in patients (MBC only)  
  
 
 
Figure 8 Proportion usage years 2006-2008, in units (MBC and EBC) 
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Paper 4 (Cost-effectiveness of HER2 re-testing and trastuzumab treatment in 
patients with metastatic breast cancer): Please see table 3 in materials and 
methods for definition of strategies. The baseline strategy, not to re-test HER2 
status, and treat all patients with chemotherapy only (Strategy 0), was least effective 
and least costly. To re-test all relapses with IHC and to FISH test IHC 2+ and 3+ 
(Strategy 4) had the lowest ICER compared to Strategy 0. The detailed results are 
presented in table 7. 
 
 
Table 7 ICER of re-testing HER2 status in metastatic breast cancer patients 
Strategy QALYs 
gained 
LYG Cost 
 
USD  
SEK 
ICER per 
QALY 
 
USD 
SEK 
ICER per 
LYG 
 
USD 
SEK 
0 No re-testing, 
chemotherapy 
alone 
1.309 1.911 41,380 
297,500 
  
1 No re-testing. 
Trastuzumab to 
previously known 
HER2 positive 
patients 
1.501 2.192 53,030 
381,300 
Dominated 
2) 
Dominated 
2) 
2 IHC re-testing. 
Trastuzumab to 
IHC 3+ patients 
1.466 2.140 50,400 
362,400 
Dominated 
2) 
Dominated 
2) 
3 IHC re-testing. 
Trastuzumab to 
IHC 2+ and 3+ 
patients 
1.525 2.226 56,200 
404,100 
Dominated 
1) 
Dominated 
1) 
4 IHC and FISH re-
testing. 
FISH confirmation 
of IHC 2+ and 3+. 
Trastuzumab to 
FISH positive 
patients. 
1.525 2.226 53,490 
384,600 
56,230 
404,300 
38,510 
276,900 
5 FISH re-testing of 
all patients. 
Trastuzumab to 
FISH positive 
patients. 
1.543 2.253 54,730 
393,500 
66,620 
479,000 
45,630 
328,100 
1) Simple Dominance    2) Extended Dominance 
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6 DISCUSSION 
The papers will be discussed one by one, except for the two first papers. They will 
be discussed together, as these papers contain related results.  
 
 Paper 1 (HER2 status in primary tumours and recurrence) and Paper 2 
(Clinically used breast cancer markers are instable throughout tumour 
progression)  
The main finding in Paper 1 is that there are discordances in HER2 status between 
primary tumour and recurrent sites in 6% of primary HER2 negative tumours and 
19% in primary HER2 positive tumours, which reflects a discordance rate of 10% for 
the entire study population. Paper 2 demonstrates a 32.4% change in ER status, 
41% change in PR status and 15% change in HER2 status. The small differences in 
HER2 status between the two papers reflect differences in study design (Lindström 
et al., 2010).  
 
In the multivariable analysis in paper 1 we noted (although a small sample size) a 
statistical significant increased risk of dying for patients with changed HER2 status, 
compared to patients with unchanged positive HER2 status (adjusted for age and 
year of diagnosis, ER status, PR status and stage). In paper 2 patients with stable 
ER positive tumours have similar survival as patients with a change from primary ER 
negative tumours to ER positive relapses, whereas patients with ER negative 
relapses (no matter of primary ER status) have a statistically significant worse 
overall survival (adjusted for age, year of diagnosis, PR, tumour stage, adjuvant 
endocrine therapy and adjuvant chemotherapy). 
 
Findings in relation to other data 
As demonstrated in other studies, adjuvant therapies could enhance clonal selection 
and patients with loss of ER and HER2 most likely show resistance to endocrine 
therapy and trastuzumab. (Lipton et al., 2005, Pectasides et al., 2006, Munzone et 
al., 2006, Mittendorf et al., 2009). Results also show that there seems to be an 
inborn clonal selection, as patients without prior treatment have alterations in 
tumours (Lindström et al., 2010, Chambers et al., 2002). Other research groups 
have also shown that it is important to re-test HER2 and ER status in recurrences 
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and metastases, as re-testing may avoid the risk of incorrect diagnosis of metastatic 
breast cancers (e.g. benign condition or other malignancy) (Amir and Clemons, 
2009, Cottu et al., 2008, Kaufmann and Pusztai, 2010, Shah et al., 2009, Simmons 
et al., 2009).  
 
Of the patients in paper 1 with stable HER2 positive status, 86% received 
trastuzumab treatment (11% as adjuvant treatment) which may have had a positive 
effect on outcome in this patient group, as shown in previous studies (Marty et al., 
2005, Slamon et al., 2001). Furthermore, the majority of relapse samples were 
analysed with FISH and Dowsett and colleagues showed that FISH HER2 positive 
tumours respond to trastuzumab treatment irrespective of the IHC result (Dowsett et 
al., 2009). The better outcome for patients with stable positive HER2 status in paper 
1 is in line with a publication on neoadjuvant treatment with trastuzumab, in which 
patients retaining a positive HER2 status had better prognosis compared with 
patients with changed HER2 status (Mittendorf et al., 2009). 
 
Strengths and weaknesses 
Data sources 
The overall strength with the patient samples in the two papers is that they are 
derived from a population based cohort from the Stockholm catchment area. The 
obvious drawback of the two papers is that they present retrospective data. This is 
also illustrated by the fact that there are differences in the base line characteristics 
between the study sample and the total sample (excluding the study sample) in 
paper 1, see table 4. The study sample also received adjuvant treatment at a higher 
degree, indicating more aggressive disease, as shown in the much shorter time to 
recurrence. The sample size in paper 1 may seem small, although the very few 
larger studies demonstrate similar results, which also strengthen our study (see also 
table 2) (Liedtke et al., 2009, Lower et al., 2009). There are a few studies including 
patients at diagnosis of relapse (Pectasides et al., 2006, Thomson et al., 2010).  
 
 
 
 
 
  
 
  35   
Technical issues 
There are also issues with both sampling techniques and analysis methods. The 
choice of sampling technique may be of importance, and there are advantages and 
disadvantages with both Fine Needle Aspirate (FNA) and Core Needle Biopsy 
(CNB) (Barra Ade et al., 2008), but from our experience the FNA technique is well 
suited for tumour sampling, although CNB is better than FNA at preoperative 
diagnosis of screen-detected breast cancer as it misses fewer cancers (Lieske et al., 
2006). However, combining FNAC resulted in a better preoperative diagnosis rate. It 
is also very important to correctly target the areas for sampling of recurrences and 
therefore collaboration between the pathologist, radiologist and oncologist is 
essential (Lindström et al., 2010).  
There is an issue with false results with IHC/ICC (sensitivity 92.6%, specificity 
98.8% IHC 3+ and 50% IHC 2+ and 3+, 7% of IHC 0/1+ FISH positive) (Elkin et al., 
2004, Yaziji et al., 2004). The majority of FNAs were analysed with FISH for HER2. 
The testing was done at one laboratory and by very few and well trained personnel 
(different staff for the ER/PR and HER2 analyses), which would support the 
reliability of the results (Ryden et al., 2009, Wilking et al., 2011, Perez et al., 2002, 
Roche et al., 2002). The HER2 IHC/ICC analyses were carried out with 2-3 
antibodies from 2000 to March 2005. There was also an internal control which 
consisted of four breast cancer cell lines. This will most probably enhance the 
reliability of the IHC/ICC results. 
 
Clinical relevance 
The observations in papers 1 and 2 have been challenged and questions are raised 
whether the change in tumour markers are artefacts or of real clinical importance. 
Some claim that it will only be feasible to take a tumour sample when there are 
clinical indications to do so, i.e. when a previous analysis was expected to be false 
or if there is suspicion for a changed response to treatment (Khasraw et al., 2011, 
Pusztai et al., 2010). On the other hand, we found that there are clinical implications 
for the change, as survival is affected, both in relation to ER change and to HER2 
change. Conflicting results also show that tumours and recurrences are either 
heterogeneous or homogenous. Foci with variable morphology and marker 
expressions show that cancers could either be heterogeneous for HER2 status, or 
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different clone expansions may explain the altered findings in recurrent lesions 
(Andersson et al., 2004, Wu et al., 2008, Staaf et al., 2010).  
 
 
Table 8 Methods for assessing ER and PR status in paper 2 
Measurement method
Primary tumor Number Percent Number Percent Total
IHC or ICC 153 33.3 5 1.1 158
Immunoassay 258 56.2 43 9.4 301
Total 411 89.5 48 10.5 459
Measurement method
Primary tumor Number Percent Number Percent Total
IHC or ICC 134 31.2 2 0.5 136
Immunoassay 249 57.9 45 10.5 294
Total 383 89.1 47 10.9 430
Table 4S: Measurement method to assess ER and PR status in primary tumor and relapse
IHC or ICC Immunoassay
ER 
PR
Relapse
IHC or ICC Immunoassay
Relapse
 
 
 
The results in paper 2 are based on both biochemical receptor determinations and 
IHC/ICC (see table 8). Even if different methods were used, there were similar ER 
concordant and discordant percentages. Furthermore, data from the Karolinska 
Hospital (based on 683 patients with diagnosis during the same time period as the 
present study) revealed a concordance value of 88% between the IHC and the 
cytosol based assays (Lofgren et al., 2003). The findings in paper 2 therefore 
strongly indicate that the observed ER changes are reflections of true biological 
alterations and not related to methodological factors.  
 
Conclusions 
The findings in papers 1 and 2 broaden the understanding of tumour biology and 
demonstrate that some tumour markers seem to lack stability throughout tumour 
progression. Changes in tumour marker status have prognostic and predictive 
implications. In other words, our results show that it is essential to retest any 
recurrence for tumour marker status in order to be able to offer correct treatment, as 
over treatment will increase the risk of side effects and under-treatment may result 
in a missed treatment effect. Further (prospective) studies are required. 
  
 
  37   
 
Paper 3 (Uptake and usage of trastuzumab in Sweden)  
Paper 3 shows that the use of trastuzumab was low during the first years after 
approval; 11% received treatment in year 2000 and the usage in the HCRs was 17-
57% for the period 2000-2004. After early breast cancer introduction of trastuzumab 
in 2005 (curative intent) there were still large differences between HCRs (43-75% of 
all HER2 positive breast cancer patients treated). These differences remained, even 
eight years after introduction. 
 
 
 
Figure 9 Population based sales in the six HCRs in Sweden years 2000-2010.  
Black – North HCR, orange – Stockholm-Gotland HCR, blue- Sweden average, 
pink, South East HCR, Red-South HCR, green Uppsala-Örebro HCR, Turquoise- 
West HCR 
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As seen from figure 9, there are large differences in sales over time. The adjuvant 
introduction in 2005 is illustrated with a “leap up” in usage in all HCRs. In the latter 
years the level of difference was reduced to 40% from 300% during the first four 
years. One can also observe some changes after year 2008. For instance, the North 
HCR, Stockholm-Gotland HCR and Uppsala-Örebro HCR have reached a plateau, 
even if we do not know if this is the maximum expected usage. The three other 
HCRs are still increasing their usage and only the future will tell when these HCRs 
have reached their maximum level of usage.  
It is worth mentioning that early introduction of adjuvant treatment may have 
resulted in fewer relapses during the time period. Early introduction will reduce the 
number of patients in need of treatment for metastatic disease, as we know from the 
adjuvant data that trastuzumab treatment will reduce the risk of recurrence with 
around 40% after 5 years (Slamon, 2009). 
 
Findings in relation to other data 
These differences are also seen in the introduction and uptake of trastuzumab 
between countries, with an almost fourfold difference between the countries in 
Europe with the lowest use (UK approx. EUR 6,000) and the highest use 
(Switzerland approx. EUR 22,000) related to mortality, as seen in figure 10 (Wilking, 
2008). The difference in usage is seen also for other cancer drugs, with large 
differences between countries and drugs. In general, countries with a lower income 
per capita have a slower uptake, despite the fact that drugs account for a large part 
of total health care spending in these countries. (Wilking N et al., 2009).   
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Figure 10 Trastuzumab sales per death in selected countries the first six years 
after approval in each country. 
From (Wilking, 2008) 
 
Strengths and weaknesses 
Used databases 
All trastuzumab sales are handled through the wholesaler system, and thus, all 
sales in the HCRs in Sweden are captured. The validation study of the breast 
cancer registration in Sweden shows that the registration is of good quality 
(Holmberg et al., 2009).  
 
Some of the factors which could have contributed to the differences in usage 
between HCRs are listed below. 
 
Proportion of patients with HER2 positive tumours 
The proportion of HER2 early positive breast cancer patients in Sweden vary in the 
reports between 14 and 19% (Ryden et al., 2005, Slamon et al., 1987, Sjogren et 
al., 1998) and many studies in MBC refer to a level of 30%, or higher (Slamon et al., 
 
Year 1 to year 6 after approval  
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1987, Wilking et al., 2011). The proportion of HER2 positive early breast cancer 
patients differed between HCRs (North HCR 11.4% South HCR 14.6% HER2 
positive). This is most probably not a real difference, but is most likely related to the 
difference in proportion tested (North HCR 100% and South HCR 84%). The levels 
of 14% and 25% HER2 positive early breast cancers and metastatic breast cancers 
were used in the estimates not to overestimate the number of breast cancer patients 
in need of treatment. Taken together this indicates that differences in HER2 
positivity between HCRs does not explain the different levels of usage. 
 
Treatment length 
Treatment lengths vary largely for metastatic breast cancer. The pivotal clinical 
study had a median treatment time of 36-40 weeks, with a range of 1-171 weeks  
(Slamon et al., 2001) and, in the encoded database, based on observational data of 
metastatic breast cancer patients, the average treatment time was 52 weeks and the 
median 36 weeks (range 1-324 weeks). Some HCRs may have continued to treat 
with trastuzumab beyond progression, substituting the cytotoxic agent, while others 
may have stopped trastuzumab treatment at progression or earlier. There is recent 
data from a randomised study showing that trastuzumab given beyond progression 
will significantly prolong TTP and PFS (von Minckwitz et al., 2009, Blackwell et al., 
2010) and this is now a recommended approach by many, although it is not based 
on the highest level of evidence (SweBCG, 2011, Cardoso et al., 2010).  
 
Patients with HER2 negative tumours 
There is some data on minor effects of trastuzumab in patients with HER2 negative 
metastatic breast cancers (Ardavanis et al., 2008). If this is hidden positive HER2 
(extracellular HER2) (Meng et al., 2004, Pusztai et al., 2010), or if there are other 
mechanisms behind is not known (Ardavanis et al., 2008, Fornier et al., 2005). 
There is also an ongoing prospective study evaluating trastuzumab in HER2 IHC 1+ 
and 2+ HER2 high risk early breast cancer patients (node negative or node positive) 
(NSABP(B-47), 2011). Some HCRs may therefore have treated single patients with 
HER2 negative or IHC 1+ or 2+ tumours, either intentionally, or unintentionally due 
to methodological deficiencies. 
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Small tumours 
Data shows that patients with small, node-negative HER2 positive early breast 
cancer may benefit from adjuvant trastuzumab treatment (Curigliano et al., 2009, 
Gonzalez-Angulo et al., 2009, Untch et al., 2008) and HCRs may offer treatment to 
some of these patients with higher risk of recurrence.  
 
Cardiac risk and age 
The perception of the cardiac risk (CHF occur in 0.38-4.3% of patients) with 
trastuzumab treatment may differ between HCRs and some HCRs may not treat 
patient above a certain age or with pre existing cardiac conditions (Dang et al., 
2010, Perez et al., 2008, Suter et al., 2007, Ewer et al., 2005). We see that older 
people have poorer survival rates and, in general, this is probably based on lower 
proportion of treated patients in older age groups (Foukakis et al., 2011).  
 
Budget factors 
Trastuzumab treatment comes at a relatively high price, compared to the previous 
standard of care (SEK 25,000 per month) and this cost is added to other treatment 
costs. The trastuzumab price likely results in differences in priorities, based on 
different budget constrain in the HCRs. The cardiac monitoring during trastuzumab 
treatment may also be considered to be a budget burden, although our estimate in 
paper 4 of the monthly cost for cardiac monitoring was only USD 120 (SEK 864). 
Furthermore, one of the smallest HCRs (low taxation base), the North HCR has the 
highest usage. This indicates that there are other factors involved. 
 
Conclusions 
There are differences between HCRs in budget priorities, interpretations of 
published data and national and international guidelines, resulting in differences in 
the size of the aimed target population, resulting in different treatment patterns.  
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Paper 4 (Cost-effectiveness of HER2 re-testing and trastuzumab treatment in 
patients with metastatic breast cancer)  
Paper 4 shows that re-testing of HER2 status in metastatic breast cancer patients 
before initiating trastuzumab is cost-effective, with a cost per QALY gained between 
USD 56,000 and USD 67,000 and cost per LYG between USD 39,000 and USD 
46,000, based on a switch of 10% in HER2 status in either direction (from HER2 + to 
HER2 – and from HER2 – to HER2 +).  
 
The consequences of the two switches in HER2 status are different. If patients 
switching to negative are treated there will be no benefits, only costs for 
trastuzumab and side effects (testing has a cost-saving effect) (Simon and 
Maitournam, 2004). A switch from HER2 negative to HER2 positive will add costs 
and side effects of treatment, but will also improve outcome. Even if the HER2 test 
and trastuzumab were costless, re-testing would be a dominant strategy and should 
always be done.  
 
Findings in relation to other data 
A previous Swedish cost-effectiveness study on trastuzumab treatment in metastatic 
breast cancer patients showed higher ICER compared to our results, although this 
study did not include re-testing of relapses in the analyses. The results in both that 
study and our study were sensitive to change in IHC sensitivity and specificity and 
improving the IHC method would affect the results in our study (Lidgren et al., 
2008b). The early studies concluded that trastuzumab usage in metastatic breast 
cancer is not cost-effective, but the improved survival may most likely alter the 
conclusion (Norum et al., 2005), as is seen in our study, based on the Marty study 
(Marty et al., 2005).  
 
There is no international consensus on HER2 testing of metastatic breast cancer, 
although the Swedish guidelines for breast cancer treatment recommend re-testing 
of HER2 status in metastatic breast cancer patients and trastuzumab treatment on 
the basis of HER status of re-testing (SweBCG, 2011).  
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Strengths and weaknesses 
Change in HER status  
The used proportion of HER2 change between primary tumour and relapse of 10% 
is a conservative level. One could argue that this low level of change in HER2 would 
not make any difference, but our sensitivity analysis showed that the change had to 
drop below 5% before re-testing could be questioned. Actually it seems that the 
level of change is higher as showed at ASCO 2010 Lindstrom presented a summary 
on available studies, and switch proportion in HER2 status ranged from 0 to 38% 
and the total reported numbers of patients with change in HER2 status were 403 of 
the 2,512 included in the studies (Lindström et al., 2010).  
 
Data sources 
One could argue that local data sources should be chosen to be able to achieve the 
most relevant results (Ferrusi et al., 2011). We used QoL data from a Swedish study 
(Lidgren et al., 2007b), although the survival data was taken from the study by Marty 
(Marty et al., 2005), as there are no later studies including an untreated metastatic 
patient population. We also used resource data and costs from the Stockholm 
County. One could also argue that data from Swedish clinical practice should be 
used. As a consequence of this, we made a sensitivity analysis on data from the 
encoded database, based on observational data of metastatic breast cancer 
patients from Stockholm. In the analyses treatment costs were higher, as treatments 
were given longer (both trastuzumab/chemotherapy and progression drugs). Results 
were otherwise similar, if the assumption holds that no survival gain is achieved 
from the longer treatment durations (see table 9). 
 
Table 9 Sensitivity analyses based on data from encoded metastatic breast 
cancer database. 
 Strategy QALYs gained Cost 
(USD) 
ICER 
(USD/QALY) 
0 1.309 39,000  
2 1.466 49,040 Dominated** 
1 1.501 52,090 Dominated** 
4 1.525 52,420 62,350 
3 1.525 55,770 Dominated* 
5 1.543 53,770 72,750 
*Simple dominance. **Extended dominance. 
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Patients with HER2 negative breast cancer 
Some may suggest that only patients with HER2 negative early breast cancer 
should undergo HER2 testing of tumour samples in the metastatic setting (Pusztai et 
al., 2010). The results showed that re-testing of only metastatic breast cancer 
patients, who had HER2 negative early breast cancer, was dominated by re-testing 
tumour samples of all metastatic breast cancer patients.  
There is data showing that trastuzumab may have an effect in HER2 negative 
patients, but most probably these patients have either false negative HER2 results 
or hidden HER2 positive disease (i.e. extra cellular HER2) (Ardavanis et al., 2008, 
Fornier et al., 2005). If later research would show a substantial benefit of 
trastuzumab in HER2 negative metastatic breast cancer patients, similar to the 
effect on HER2 positive metastatic breast cancer patients, we would have to revise 
our results. As mentioned before, there is actually an ongoing study in early breast 
cancer patients with HER2 IHC 1+ and 2+ disease (NSABP(B-47), 2011).  
 
Conclusions 
Paper 4 shows that re-testing of HER2 status in metastatic breast cancers is cost-
effective. It is also important to carry out testing from a clinical perspective, as both 
under- and over-treatment is avoided. 
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7 CONCLUDING REMARKS 
Optimal management of small targeted patient populations is a challenge, as with 
the HER2 positive breast cancer patient population, and there are many aspects to 
consider. 
Our studies revealed that it is important to define the patient population correctly, in 
primary and metastatic settings. There is a lack of stability of both HER2 and 
hormone receptors, being specific targets for anti HER2 and endocrine agents.  
Our studies also revealed that there are clinical and economic rationales for re-
biopsying breast cancer patients with clinical and/or radiological diagnosed 
recurrences.  
 
The knowledge created in this thesis could be used for the introduction of future co-
dependent technologies, in order to gain the most health benefits, both to patients 
and to society, which should be applicable to upcoming new targeted agents and 
related diagnostic procedures. 
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